CureVac's CV7202 is an innovative mRNA-based rabies vaccine currently in Phase 1 clinical trials. The vaccine aims to provide a safer and potentially more effective alternative to traditional rabies vaccines. The market for rabies vaccines is significant, particularly in regions with high rabies incidence. Competitive advantages may arise from the use of mRNA technology, which has shown promise in rapid vaccine development and adaptability. However, the company must navigate existing patents and regulatory pathways to ensure successful market entry. The completion of this trial could position CureVac favorably against established players in the rabies vaccine market.